$1.15
-0.01 (-0.86%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MRKR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 3.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety of MT-401-OTS in Patients With Relapsed AML or MDSNCT06552416Safety of MT-401-OTSNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: MT-401-OTS | Acute Myeloid Leukemia, in Relapse, MDS | 40 | Sep 2029 | ≤ 1,138 d | 2025-12-16 |
| MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic CancerNCT06549751During Dose Escalation - determine the MTD, recommended expansion dose, or MPD of MT-601 administered during maintenance capacitabine following treatment with FOLFIRINOX (FFX) or NALIRIFOX (NLX).Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells, MT-601 dose 1200 million cells | Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable) | 38 | 2028-07-16 | in 697 d | 2026-05-13 |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaNCT05798897Dose EscalationOpen-label · Treatment | Phase 1 | Recruiting | Drug: MT-601 | Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult | 79 | 2028-02-28 | in 558 d | 2025-08-20 |
| Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantNCT04511130Safety Lead-InRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401. | Drug: MT-401 | Acute Myeloid Leukemia, Stem Cell Transplantation | 92 | 2024-03-01actual | — | 2025-10-30 |
| Plasma Adsorption in Patients With Confirmed COVID-19NCT04358003All-cause mortalityOpen-label · Treatment | Not applicable | Completed | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) | Respiratory Failure, ARDS | 107 | 2021-11-26actual | — | 2022-04-11 |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast CancerNCT02593227Immune responseRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: Low dose FRα vaccine, High dose FRα vaccine · Drug: Cyclophosphamide | Breast Cancer | 80 | 2021-07-15actual | — | 2021-07-19 |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian CancerNCT02978222results2022-12-15Progression Free SurvivalRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Futility analysis did not support continuation of the trial | Biological: FRα peptide plus Adjuvant (GM-CSF) · Drug: Adjuvant (GM-CSF) Alone | Platinum Sensitive Ovarian Cancer, Ovarian Cancer | 120 | 2020-01-15actual | — | 2022-12-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19